Within two to four weeks we find potential targets/biomarker candidates or do a detailed target/biomarker assessment. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll contact you to discuss next steps.

Use our platform to find novel target/biomarker candidates or do detailed target/biomarker assessment yourselves. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll set up a demo to show you!

Please contact me to discuss:

Subscription to Euretos AI Platform
Euretos consulting service
Direct access to Euretos API

Do you have a question on gene-disease associations that are not covered on this page? Or would you like to know more about the Euretos AI Platform? Please fill in your contact details and we will reach out to you!




Euretos presenting at the Target & Biomarker Discovery track at BioEurope 2019 in Hamburg



Monday 28 October 2019

Arie Baak, co-founder of Euretos, will be presenting, for the second year in a row, at Bio Europe. This year’s event will take place in Hamburg and Euretos will present as part of the Target & Biomarker Discovery track, November 12th at 11:45, Hall B1, Room 7.

 

To help bring entrepreneurial companies to the attention of pharma, biotech and investors, BIO-Europe features a limited number selected presentation slots. In order to be selected, presenting companies need to be developing new therapeutic products or offering an innovative service. A panel of industry experts evaluated the applications and Euretos was selected as being among the companies having the greatest potential interest for partnering, consistent with the event's focus.

 

Euretos will present on how it’s applications and services give researchers fundamental and novel insights into the systems biological, molecular mechanisms that drive phenotypes, disease pathologies, toxicities and drug response.

 

Euretos uses Machine Reading to semantically integrate over 275 public life sciences data and textual sources to provide the largest knowledge base where multi omics data is interlinked to literature, patents, experimental and clinical evidence. 

 

State-of-the-art Machine & Deep Learning algorithms for cell type deconvolution, co-expression prediction and target perturbation analysis leverage this unique knowledge base to create highly insightful molecular disease models.

 

These unique assets enable (pre)clinical researchers to take a translational systems biology approach by connecting multi-omics interactions, through cell-type involvement, to downstream pathways, phenotypes and disease pathologies.


Please contact us at www.euretos.com if you would like to meet during the event!